Have any questions? 706-721-6582 or cts@augusta.edu
- (CD12) A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients with Severe or Critical Coronavirus Disease 2019 (COVID-19)
Clinical Trial
(CD12) A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients with Severe or Critical Coronavirus Disease 2019 (COVID-19)
This study is for adults ages 18 and older who have a severe COVID-19 infection. The purpose is to see if a drug, Leronlimab (PRO 140), is a safe and effective treatment.
Eligibility Criteria
- To be eligible, subjects must * be 18 of age or older * have a confirmed diagnosis of SARS-CoV-2 * be hospitalized * be free of other serious or underlying health conditions or recent history of health events
RESEARCH. INNOVATION. DISCOVERY.